Related News

No related news articles were found.

avax technologies inc (AVXT) Related Businessweek News

No Related Businessweek News Found

avax technologies inc (AVXT) Details

AVAX Technologies, Inc., a development stage biopharmaceutical company, specializes in the development and commercialization of vaccine therapies and other technologies for the treatment of cancer. The company’s autologous cell vaccine immunotherapy products include M-VAX intended for the treatment of melanoma is under phase II clinical trials; and O-VAX intended for the treatment for ovarian cancer is under phase I/II trials. It also provides contract manufacturing and research services. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

avax technologies inc (AVXT) Key Developments

AVAX Technologies Inc. announced that it has expanded its ongoing Phase 1/2 study ("Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients with relapsed Stage III or IV Ovarian Cancer") to include all five Cancer Treatment Centers of America(R) (CTCA) regional hospitals. In addition, clinical data from the study was selected to be presented at the Society of Gynecologic Oncology ("SGO") 19(th) Annual Winter Meeting February 20 -- 22, 2014 at Breckenridge, Colorado. The SGO is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.